Next generation vaccine technology platform
Affinivax is developing novel vaccines based on its proprietary technology platform the Multiple Antigen Presenting System (MAPS). Working with world experts in vaccine discovery and development Affinivax is building a pipeline of innovative vaccines to achieve broader protection against a wide range of diseases including those for which there are no effective vaccines available today.
|Human health & social work||Operating||2 - 10 employees|
Funding and Financing Rounds
Jun, 2014 / PRI / Cash & Convertible Note
Impact Reports & Metrics
Cambridge, Massachusetts United States of America